Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care ...( PT. RICHMOND Calif. Nov. 24 /- Tr...),Health

PT. RICHMOND, Calif., Nov. 24 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York City on Tuesday, December 2, 2008 at 8:00 AM Eastern Time.

An audio webcast of the presentation will be available at http://www.piperjaffray.com/conferences. The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration.

For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of Transcept product candidates. Such statement
'/>"/>